📰 Jon Patton News
Page 4 - Jon Patton News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Jon Patton. Real-time updates on events, politics, business and more.
May 25, 2023
31% week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off... | June 11, 2023
May 10, 2023
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders...
May 5, 2023
Randomized phase 2 data from BRACELET-1 trial in HR+/HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical...
May 5, 2023
Randomized phase 2 data from BRACELET-1 trial in HR+/HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Guidance
May 3, 2023
Riley Beveridge takes a look at how Tasmania could build its list
April 26, 2023
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract for an oral presentation at the American...
April 26, 2023
Oral presentation on BRACELET-1 to take place on June 3, 2023 SAN DIEGO and CALGARY, AB, April 26, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced
April 18, 2023
The AFL has moved to tighten its inactive player rules ahead of the mid-season draft in May
April 12, 2023
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is pleased to announce its notice of the annual general meeting of shareholders and...
April 12, 2023
Conference call and webcast to take place on Friday, May 5, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: